Published in Br J Cancer on May 18, 2001
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 18.40
The pancreas cancer microenvironment. Clin Cancer Res (2012) 4.10
Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol (2012) 4.00
Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology (2008) 3.95
A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res (2009) 3.38
Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc (2009) 3.36
Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer (2010) 3.33
Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol (2007) 3.03
Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov (2014) 2.98
Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell (2012) 2.61
Mouse xenograft models vs GEM models for human cancer therapeutics. Dis Model Mech (2008) 2.37
The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther (2008) 1.90
Designing phase 0 cancer clinical trials. Clin Cancer Res (2008) 1.85
Antitumor efficacy testing in rodents. J Natl Cancer Inst (2008) 1.80
Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies. Eur J Cancer (2008) 1.70
Experimental models of hepatocellular carcinoma. J Hepatol (2008) 1.61
Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin Cancer Res (2011) 1.59
Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nat Rev Drug Discov (2010) 1.59
Metastatic behaviour of primary human tumours in a zebrafish xenotransplantation model. BMC Cancer (2009) 1.47
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing. Pediatr Blood Cancer (2010) 1.47
Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids. J Biol Chem (2008) 1.45
Hydrodynamic transfection for generation of novel mouse models for liver cancer research. Am J Pathol (2014) 1.44
Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy. PLoS One (2015) 1.44
Patient-derived xenograft models of breast cancer and their predictive power. Breast Cancer Res (2015) 1.43
Xenograft models of head and neck cancers. Head Neck Oncol (2009) 1.37
Hepatocellular carcinoma: insight from animal models. Nat Rev Gastroenterol Hepatol (2011) 1.28
A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. Mol Oncol (2013) 1.28
Preclinical development of molecular-targeted agents for cancer. Nat Rev Clin Oncol (2010) 1.27
Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance. Clin Cancer Res (2012) 1.24
A meta-analysis of threats to valid clinical inference in preclinical research of sunitinib. Elife (2015) 1.20
Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest. Cancer Immunol Res (2014) 1.17
Molecular characterization of patient-derived human pancreatic tumor xenograft models for preclinical and translational development of cancer therapeutics. Neoplasia (2013) 1.17
Resection of the primary tumor improves survival in metastatic breast cancer by reducing overall tumor burden. Surgery (2013) 1.16
Patient-derived xenografts of non small cell lung cancer: resurgence of an old model for investigation of modern concepts of tailored therapy and cancer stem cells. J Biomed Biotechnol (2012) 1.14
Translational considerations for cancer nanomedicine. J Control Release (2010) 1.12
Comparison of IgG diffusion and extracellular matrix composition in rhabdomyosarcomas grown in mice versus in vitro as spheroids reveals the role of host stromal cells. Br J Cancer (2002) 1.11
Oncologic phase 0 trials incorporating clinical pharmacodynamics: from concept to patient. Clin Cancer Res (2008) 1.11
New cast for a new era: preclinical cancer drug development revisited. J Clin Invest (2013) 1.11
The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy. PLoS One (2011) 1.11
HLA class I and II genotype of the NCI-60 cell lines. J Transl Med (2005) 1.11
Chronic stress accelerates pancreatic cancer growth and invasion: a critical role for beta-adrenergic signaling in the pancreatic microenvironment. Brain Behav Immun (2014) 1.09
Molecular characterization of putative chordoma cell lines. Sarcoma (2010) 1.09
Use of the in vivo hollow fiber assay in natural products anticancer drug discovery. J Nat Prod (2009) 1.09
Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue. J Transl Med (2012) 1.07
Patient-derived cell models as preclinical tools for genome-directed targeted therapy. Oncotarget (2015) 1.06
Nitric oxide and cancer therapy: the emperor has NO clothes. Curr Pharm Des (2010) 1.05
Nm23-H1 metastasis suppressor expression level influences the binding properties, stability, and function of the kinase suppressor of Ras1 (KSR1) Erk scaffold in breast carcinoma cells. Mol Cell Biol (2005) 1.05
An improved syngeneic orthotopic murine model of human breast cancer progression. Breast Cancer Res Treat (2014) 1.03
Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients. J Pathol (2011) 1.02
Transforming growth factor-β signalling controls human breast cancer metastasis in a zebrafish xenograft model. Breast Cancer Res (2013) 1.02
Systematic reviews of animal models: methodology versus epistemology. Int J Med Sci (2013) 1.01
Development and characterization of xenograft model systems for adenoid cystic carcinoma. Lab Invest (2011) 1.01
Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clin Cancer Res (2014) 1.01
Ex vivo culture of human prostate tissue and drug development. Nat Rev Urol (2013) 1.00
Animal models and conserved processes. Theor Biol Med Model (2012) 0.99
Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges. Cell (2015) 0.99
Identification of Simple Compounds with Microtubule-Binding Activity That Inhibit Cancer Cell Growth with High Potency. ACS Med Chem Lett (2011) 0.98
Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. Cancer Lett (2014) 0.97
Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAF. Oncogene (2013) 0.97
A framework to select clinically relevant cancer cell lines for investigation by establishing their molecular similarity with primary human cancers. Cancer Res (2011) 0.97
Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes. Hum Genet (2011) 0.96
A quantitative volumetric micro-computed tomography method to analyze lung tumors in genetically engineered mouse models. Neoplasia (2009) 0.94
Re-adapting T cells for cancer therapy: from mouse models to clinical trials. Immunol Rev (2014) 0.94
Patient-derived xenograft models for pancreatic adenocarcinoma demonstrate retention of tumor morphology through incorporation of murine stromal elements. Am J Pathol (2015) 0.94
The impact of the myeloid response to radiation therapy. Clin Dev Immunol (2013) 0.92
Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice. Br J Pharmacol (2012) 0.92
Preclinical therapeutic response of residual metastatic disease is distinct from its primary tumor of origin. Int J Cancer (2011) 0.91
Recapitulation of tumor heterogeneity and molecular signatures in a 3D brain cancer model with decreased sensitivity to histone deacetylase inhibition. PLoS One (2012) 0.90
Assessment of a novel VEGF targeted agent using patient-derived tumor tissue xenograft models of colon carcinoma with lymphatic and hepatic metastases. PLoS One (2011) 0.90
Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer. BMC Cancer (2007) 0.89
Illuminating cancer systems with genetically engineered mouse models and coupled luciferase reporters in vivo. Cancer Discov (2013) 0.89
A strategy for integrating essential three-dimensional microphysiological systems of human organs for realistic anticancer drug screening. Exp Biol Med (Maywood) (2014) 0.89
Prioritizing therapeutic targets using patient-derived xenograft models. Biochim Biophys Acta (2015) 0.88
Multiplexing spheroid volume, resazurin and acid phosphatase viability assays for high-throughput screening of tumour spheroids and stem cell neurospheres. PLoS One (2014) 0.88
Temperature-sensitive magnetic drug carriers for concurrent gemcitabine chemohyperthermia. Adv Healthc Mater (2013) 0.88
Esophageal Cancer: Insights From Mouse Models. Cancer Growth Metastasis (2015) 0.88
Preclinical predictors of anticancer drug efficacy: critical assessment with emphasis on whether nanomolar potency should be required of candidate agents. J Pharmacol Exp Ther (2012) 0.87
Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer. J Gastroenterol (2011) 0.87
Animal models for exploring the pharmacokinetics of breast cancer therapies. Expert Opin Drug Metab Toxicol (2014) 0.87
Targeted therapy of spontaneous murine pancreatic tumors by polymeric micelles prolongs survival and prevents peritoneal metastasis. Proc Natl Acad Sci U S A (2013) 0.87
Integrated analysis of preclinical data to support the design of the first in man study of LY2181308, a second generation antisense oligonucleotide. Br J Clin Pharmacol (2011) 0.87
MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer. Mol Cancer (2011) 0.86
A novel ligand-independent peptide inhibitor of TREM-1 suppresses tumor growth in human lung cancer xenografts and prolongs survival of mice with lipopolysaccharide-induced septic shock. Int Immunopharmacol (2014) 0.85
Next generation patient-derived prostate cancer xenograft models. Asian J Androl (2014) 0.85
Overview of human primary tumorgraft models: comparisons with traditional oncology preclinical models and the clinical relevance and utility of primary tumorgrafts in basic and translational oncology research. Curr Protoc Pharmacol (2012) 0.85
Development of flexible-heteroarotinoids for kidney cancer. Mol Cancer Ther (2009) 0.85
Influence of handling conditions on the establishment and propagation of head and neck cancer patient derived xenografts. PLoS One (2014) 0.85
Reporting of preclinical tumor-graft cancer therapeutic studies. Cancer Biol Ther (2012) 0.85
Species differences in tumour responses to cancer chemotherapy. Philos Trans R Soc Lond B Biol Sci (2015) 0.85
A short-term colorectal cancer sphere culture as a relevant tool for human cancer biology investigation. Br J Cancer (2013) 0.84
Generation of Multicellular Tumor Spheroids with Microwell-Based Agarose Scaffolds for Drug Testing. PLoS One (2015) 0.84
Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapies. Oncotarget (2015) 0.83
Establishment and characterisation of patient-derived xenografts as paraclinical models for gastric cancer. Sci Rep (2016) 0.83
Preclinical models of pancreatic ductal adenocarcinoma. J Pathol (2015) 0.83
Challenges in pre-clinical testing of anti-cancer drugs in cell culture and in animal models. J Control Release (2012) 0.83
Personalising pancreas cancer treatment: When tissue is the issue. World J Gastroenterol (2014) 0.82
Primary orthotopic glioma xenografts recapitulate infiltrative growth and isocitrate dehydrogenase I mutation. J Vis Exp (2014) 0.82
An Integrative Approach to Precision Cancer Medicine Using Patient-Derived Xenografts. Mol Cells (2016) 0.82
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res (1988) 9.96
Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst (1991) 9.39
Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst (1989) 4.97
A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J Comb Chem (1999) 3.09
Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res (1999) 2.58
Correlation of drug response in patients and in the clonogenic assay with solid human tumour xenografts. Eur J Cancer (1990) 1.49
Preclinical drug development: rationale and methods. Semin Oncol (1981) 1.32
Evolving approaches to cancer drug discovery and development at the National Cancer Institute, USA. Ann Oncol (1999) 1.30
Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells: implications for anticancer drug screening programs. Cancer Res (1998) 1.29
Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976-1982, and future directions. Adv Pharmacol Chemother (1984) 1.25
History of the Cancer Chemotherapy Program. Cancer Chemother Rep (1966) 1.24
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71
A gene expression database for the molecular pharmacology of cancer. Nat Genet (2000) 13.31
An information-intensive approach to the molecular pharmacology of cancer. Science (1997) 11.43
Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg (1995) 9.51
Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst (1999) 6.51
Jasplakinolide, a cytotoxic natural product, induces actin polymerization and competitively inhibits the binding of phalloidin to F-actin. J Biol Chem (1994) 5.67
Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res (1999) 5.35
Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res (1997) 4.34
Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol (2001) 3.55
Amelogenin-deficient mice display an amelogenesis imperfecta phenotype. J Biol Chem (2001) 3.50
The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem (2000) 3.49
Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem (2000) 3.13
A comparison of two phase I trial designs. Stat Med (1994) 2.71
Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst (2000) 2.62
UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst (1996) 2.39
Neural computing in cancer drug development: predicting mechanism of action. Science (1992) 2.38
Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen. J Natl Cancer Inst (1998) 2.31
Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res (1996) 2.24
A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci U S A (2000) 2.20
Electrical stimulation for swallowing disorders caused by stroke. Respir Care (2001) 2.18
Phase I clinical trial design in cancer drug development. J Clin Oncol (2000) 2.14
Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation. J Chronic Dis (1981) 2.03
Human small-cell lung cancers show amplification and expression of the N-myc gene. Proc Natl Acad Sci U S A (1986) 1.96
Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. Eur J Biochem (2000) 1.93
dlk, a putative mammalian homeotic gene differentially expressed in small cell lung carcinoma and neuroendocrine tumor cell line. J Biol Chem (1993) 1.90
The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets. Anticancer Drug Des (1997) 1.89
Sites of recurrence in resected stage I non-small-cell lung cancer: a guide for future studies. J Clin Oncol (1984) 1.80
Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol (1998) 1.80
Phosphorylation of ribosomal protein S6 in avian sarcoma virus-transformed chicken embryo fibroblasts. Proc Natl Acad Sci U S A (1981) 1.66
Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res (2001) 1.65
Relapse or late reversal reaction? Int J Lepr Other Mycobact Dis (1989) 1.63
Expression of the lck tyrosine kinase gene in human colon carcinoma and other non-lymphoid human tumor cell lines. Oncogene Res (1988) 1.53
A role for ferrous ion and oxygen in the degradation of DNA by bleomycin. Biochem Biophys Res Commun (1976) 1.52
Validity and reliability testing of the Prenatal Psychosocial Profile. Res Nurs Health (1994) 1.48
Properties and products of the degradation of DNA by bleomycin and iron(II). Biochemistry (1978) 1.47
Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. J Med Chem (1999) 1.47
BRS-3: a novel bombesin receptor subtype selectively expressed in testis and lung carcinoma cells. J Biol Chem (1993) 1.47
Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res Commun (1994) 1.47
Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines. J Natl Cancer Inst (2000) 1.46
Jasplakinolide's inhibition of the growth of prostate carcinoma cells in vitro with disruption of the actin cytoskeleton. J Natl Cancer Inst (1995) 1.44
L-myc cooperates with ras to transform primary rat embryo fibroblasts. Mol Cell Biol (1988) 1.43
Antiviral (RNA) activity of selected Amaryllidaceae isoquinoline constituents and synthesis of related substances. J Nat Prod (1992) 1.43
Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. Cancer Res (1999) 1.41
Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res (1999) 1.40
Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res (1994) 1.37
Long-term adjustment to physical disability: the role of social support, perceived control, and self-blame. J Pers Soc Psychol (1985) 1.35
In vitro evaluation of amino acid prodrugs of novel antitumour 2-(4-amino-3-methylphenyl)benzothiazoles. Br J Cancer (2002) 1.34
Preclinical drug development: rationale and methods. Semin Oncol (1981) 1.32
Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood (1998) 1.31
Effect of chelating agents and metal ions on the degradation of DNA by bleomycin. Biochemistry (1978) 1.31
UCN-01 abrogates G2 arrest through a Cdc2-dependent pathway that is associated with inactivation of the Wee1Hu kinase and activation of the Cdc25C phosphatase. J Biol Chem (1998) 1.30
Developmental therapeutics program at the NCI: molecular target and drug discovery process. Leukemia (2002) 1.29
Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. Cancer Res (1998) 1.28
Application of a human tumor colony-forming assay to new drug screening. Cancer Res (1985) 1.26
Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976-1982, and future directions. Adv Pharmacol Chemother (1984) 1.25
The auxin signal for protoplast swelling is perceived by extracellular ABP1. Plant J (2001) 1.24
Two distinct bombesin receptor subtypes are expressed and functional in human lung carcinoma cells. J Biol Chem (1991) 1.23
Cucurbitacin E-induced disruption of the actin and vimentin cytoskeleton in prostate carcinoma cells. Biochem Pharmacol (1996) 1.21
Markov models for covariate dependence of binary sequences. Biometrics (1985) 1.21
Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes. Cancer Res (1996) 1.21
Transcriptional inactivation of c-myc and the transferrin receptor in dibutyryl cyclic AMP-treated HL-60 cells. Mol Cell Biol (1987) 1.20
Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J Clin Invest (1998) 1.20
Role of Cyp1A1 in modulation of antitumor properties of the novel agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) in human breast cancer cells. Cancer Res (2000) 1.19
Bursting atlantal fracture associated with rupture of the transverse ligament. J Bone Joint Surg Am (1970) 1.17
A reassessment of cardiac toxicity associated with Taxol. J Natl Cancer Inst Monogr (1993) 1.17
The small bovine amelogenin LRAP fails to rescue the amelogenin null phenotype. Calcif Tissue Int (2003) 1.16
Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clin Cancer Res (1997) 1.15
Expression of the gastrin-releasing peptide gene in human small cell lung cancer. Evidence for alternative processing resulting in three distinct mRNAs. J Biol Chem (1986) 1.15
A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood (1996) 1.15
Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. J Med Chem (2000) 1.13
A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma. Clin Cancer Res (2000) 1.13
A protein expression database for the molecular pharmacology of cancer. Electrophoresis (1997) 1.13
Targeted toxins. Clin Cancer Res (2000) 1.12
Efficacy, pharmacokinetics, and in vivo antiviral activity of UC781, a highly potent, orally bioavailable nonnucleoside reverse transcriptase inhibitor of HIV type 1. AIDS Res Hum Retroviruses (1997) 1.12
Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Res (1999) 1.12
MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells. Cancer Res (2001) 1.12
GTPase-activating protein interactions with the viral and cellular Src kinases. Proc Natl Acad Sci U S A (1991) 1.11
Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity. Biochem Pharmacol (1993) 1.11
Structure and function of the B and D genes of the Actinobacillus actinomycetemcomitans leukotoxin complex. Microb Pathog (1991) 1.11
Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening. Cancer Res (1992) 1.10
Cell volume is a major determinant of proteolysis control in liver. FEBS Lett (1991) 1.10
Raf-1 N-terminal sequences necessary for Ras-Raf interaction and signal transduction. Mol Cell Biol (1995) 1.09
Current results of the screening program at the Division of Cancer Treatment, National Cancer Institute. Eur J Cancer (1981) 1.07
Purification of denatured epidermal growth factor-receptor from A431 human epidermoid carcinoma cells. Arch Biochem Biophys (1984) 1.07
Inhibition of CDKs as a therapeutic modality. Ann N Y Acad Sci (2000) 1.06
Duration of drug levels in mice as indicated by residual antileukemic efficacy. Chemotherapy (1968) 1.06
Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles. J Med Chem (1999) 1.05
Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue. Mol Pharmacol (1994) 1.05
Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res (1993) 1.05
Molecular features of the viral and cellular Src kinases involved in interactions with the GTPase-activating protein. Mol Cell Biol (1991) 1.05
Expression and location of pro-apoptotic Bcl-2 family protein BAD in normal human tissues and tumor cell lines. Am J Pathol (1998) 1.04
Porcine choroid plexus cells in culture: expression of polarized phenotype, maintenance of barrier properties and apical secretion of CSF-components. Eur J Cell Biol (1997) 1.04
Synthesis of 3-deazaneplanocin A, a powerful inhibitor of S-adenosylhomocysteine hydrolase with potent and selective in vitro and in vivo antiviral activities. J Med Chem (1989) 1.03
A model of mucopolysaccharidosis IIIB (Sanfilippo syndrome type IIIB): N-acetyl-alpha-D-glucosaminidase deficiency in Schipperke dogs. J Inherit Metab Dis (2003) 1.03
DNA protein cross-links produced by NSC 652287, a novel thiophene derivative active against human renal cancer cells. Mol Pharmacol (1999) 1.03
Dolastatin 11, a marine depsipeptide, arrests cells at cytokinesis and induces hyperpolymerization of purified actin. Mol Pharmacol (2001) 1.03
The effect of phenobarbital or 2-diethylaminoethyl-2,2-diphenylvalerate on the activation of cyclophosphamide in vivo. J Pharmacol Exp Ther (1972) 1.02